Major depressive disorder (MDD)

PRISTIQ® (desvenlafaxine)

PRISTIQ® (desvenlafaxine) Extended-Release Tablets

PRISTIQ® (desvenlafaxine) PRISTIQ is an extended-release tablet for oral administration that contains desvenlafaxine succinate, a structurally novel SNRI for the treatment of MDD. Desvenlafaxine (O-desmethylvenlafaxine) is the major active metabolite of the antidepressant venlafaxine, a medication used to treat major depressive disorder. Desvenlafaxine is designated RS-4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol and has the empirical formula of C16H25NO2 (free base) …

PRISTIQ® (desvenlafaxine) Extended-Release Tablets Read More »

PEXEVA® (paroxetine mesylate) tablets

PEXEVA® (paroxetine mesylate) tablets

PEXEVA contains paroxetine mesylate, an SSRI. The mechanism of action of paroxetine in the treatment of major depressive disorder (MDD), obsessive compulsive disorder (OCD), panic disorder (PD), and general anxiety disorder (GAD) is unknown

EFFEXOR XR® (venlafaxine Extended-Release) Capsules

EFFEXOR XR® (venlafaxine Extended-Release) Capsules

Effexor XR (venlafaxine hydrochloride) extended-release capsules are indicated for the treatment of major depressive disorder (MDD). Effexor XR is indicated for the treatment of Generalized Anxiety Disorder (GAD).

ZOLOFT (Sertraline hydrochloride, USP)

ZOLOFT (Sertraline hydrochloride, USP)

Sertraline potentiates serotonergic activity in the central nervous system through inhibition of neuronal reuptake of serotonin (5-HT). ZOLOFT contains sertraline hydrochloride, an SSRI.

Adblock Detected!

Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by whitelisting our website.